CS
CPRX

Candriam SCA’s Catalyst Pharmaceutical CPRX Stock Holding History

Candriam SCA’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
+55,795
New +$1.65M 0.01% 525
2017
Q4 		– Sell
-560,000
Closed -$1.41M – 757
2017
Q3 		$1.41M Hold
560,000
– – 0.02% 513
2017
Q2 		$1.55M Sell
560,000
-40,000
-7% -$83.5K 0.03% 507
2017
Q1 		$1.17M Buy
+600,000
New +$764K 0.02% 539

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Candriam SCA's CPRX Position: Q2 2026 in Review

Candriam SCA opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 55,795 shares worth $1.75M. The stake represents 0.01% of the portfolio and ranks #525 among its holdings. This is a return to the name: Candriam SCA previously reported a position in CPRX as recently as Q3 2017.

Candriam SCA first reported a position in CPRX in Q1 2017 and has held it in 4 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Candriam SCA held 55,795 shares of Catalyst Pharmaceutical worth $1.75M as of Q2 2026.
  • Catalyst Pharmaceutical was a new Candriam SCA position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.01% of Candriam SCA's portfolio in Q2 2026, its #525 holding.
  • Candriam SCA first reported a position in Catalyst Pharmaceutical in Q1 2017 and has held it in 4 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.